Ftse Mib
33.986,90
0,00%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.514,63
0,55%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MiNK Therapeutics Inc (INKT) MiNK Therapeutics Inc (INKT) Notizie

MiNK Therapeutics Inc

INKT
0,9642
-0,0158 (-1,61%)
07 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202413:30GLOBEMiNK to Provide Corporate Update and First Quarter 2024..
08/4/202418:00GLOBEMiNK Therapeutics Announces Promising Preclinical Activity..
21/3/202412:26IHMARKETNEWSU.S. Index Futures Rise as Fed’s Dovish Outlook Spurs..
21/3/202412:00GLOBEMiNK Reports Fourth Quarter and Year-End 2023 Results
07/3/202413:30GLOBEMiNK to Provide Corporate Update and Fourth Quarter & Full..
06/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:05EDGAR2Form 8-K - Current report
14/2/202414:00EDGAR2Form 8-K - Current report
14/2/202414:00GLOBEFirst Refractory Gastric Cancer Patient Dosed in Phase 2..
06/2/202414:00GLOBEMiNK Therapeutics' AgenT-797 Shows Promising Results in the..
30/1/202414:00GLOBEMiNK’s AgenT-797 Offers New Hope in Overcoming ICI..
19/1/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202313:30GLOBEImmunoScape and MiNK Therapeutics Collaborate to Accelerate..
06/12/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202313:00EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEMiNK Therapeutics Reports Third Quarter 2023 Results
03/11/202317:00GLOBEMiNK Therapeutics Presents Clinical Activity and Long-Term..
30/10/202313:00GLOBEMiNK to Provide Third Quarter 2023 Financial Report and..
17/10/202322:15EDGAR2Form 8-K - Current report
27/9/202315:05GLOBEMiNK Therapeutics To Present Data Update From Allogeneic..
06/9/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202314:30GLOBEMiNK Therapeutics to Participate in September Investor..
11/8/202313:44EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/8/202313:30EDGAR2Form 8-K - Current report
10/8/202313:30GLOBEMiNK Therapeutics Reports Second Quarter 2023 Results
10/8/202313:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28/7/202314:30GLOBEMiNK to Provide Second Quarter 2023 Financial Report and..
05/6/202313:30GLOBEMiNK Therapeutics Announces Virtual Annual Shareholders..
22/5/202314:30GLOBEMiNK Presents Clinical Data on Allogeneic iNKT Cells..
18/5/202314:30GLOBEMiNK's Novel FAP-CAR-iNKT Presented at ASGCT
11/5/202314:00GLOBEMiNK Therapeutics Reports Corporate Update and First Quarter..
Apertura: 0,98 Min: 0,9405 Max: 1,01
Chiusura: 0,98

La tua Cronologia

NASDAQ
INKT
MiNK Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network